Navigation Links
Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes
Date:4/24/2009

First study evaluating DUROS(R) continuous delivery of exenatide for the treatment of type 2 diabetes

HAYWARD, Calif., April 24 /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced the completion of patient accrual to a phase 1b clinical study evaluating ITCA 650 (DUROS(R) continuous delivery of exenatide). The study is being conducted at multiple centers in the United States and involves the treatment of 44 patients with type 2 diabetes for a period of 4 weeks.

(Logo: http://www.newscom.com/cgi-bin/prnh/20050301/SFTU126LOGO)

Intarcia began the development of ITCA 650 in 2007 after acquiring an exclusive worldwide license to the DUROS delivery technology. The DUROS delivery technology consists of the DUROS device, a matchstick-size miniature osmotic pump that is inserted subcutaneously to provide continuous and consistent drug therapy, and proprietary formulation technology that maintains stability of therapeutic proteins and peptides at human body temperature for extended periods of time. Exenatide, the active agent in ITCA 650, has been approved in the US, Europe and many other markets and is currently marketed as a twice-daily self-injection therapy for type 2 diabetes.

Intarcia's phase 1 study is evaluating the safety and pharmacokinetics of ITCA 650 at several doses over a treatment period of 4 weeks. ITCA 650 therapy is administered for the full course of therapy with a single insertion of the DUROS device on day 1 and removal on day 29. Results of the phase 1 study will support selection of doses to be evaluated in a controlled phase 2 study planned for later in 2009 in which longer durations of treatment with a single ITCA 650 insertion will be evaluated. The DUROS technology can deliver up to a full year of therapy from a single ITCA 650 insertion. The goals of the ITCA 650 program are to enha
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
2. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
3. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
4. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
5. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
6. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
7. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
8. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
9. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
10. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
11. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... -- Amgen (NASDAQ: AMGN ) today announced financial ... results include: , Total revenues increased 4 ... $5,370 million, with 6 percent product sales growth ... ® (denosumab), Sensipar ® (cinacalcet), Kyprolis ... Unfavorable changes in foreign exchange rates impacted total ...
(Date:7/30/2015)... July 30, 2015  Cleveland Clinic President Wael ... address last month that industry is compelled to adopt ... gain the efficiencies—and develop the transformational innovations -- required ... comments were preceded by Doug Kohrs , past ... moderator, who stressed that industry must add "episode of ...
(Date:7/30/2015)... YORK , July 30, 2015 /PRNewswire/ ... a new research report with market overview, ... share, forecast, porter analysis, recent developments, competitive ... Global Industry Insight: Biosensors Market Development ...      (Logo: http://photos.prnewswire.com/prnh/20150727/756778 ) ...
Breaking Medicine Technology:Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23Orthopaedic Surgery Reimbursement Shifts to Episode of Care 2Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 2Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 3Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 4Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 5
...  Novation, the leading health care supply contracting company, today ... Summary Report, Winter 2012 .  This summary report highlights ... Forecast , including projected drug price inflation summary projections ... on purchase volume. Novation,s semi-annual Drug ...
... Minn., March 22, 2012 /PRNewswire-iReach/ -- ... emerging medical technology company, today announced the publication ... K. Potter, MD, LTC Brett A. Freedman, MD, ... National Military Medical Center, Bethesda, MD, describing their treatment ...
Cached Medicine Technology:Novation Releases its Drug Price Forecast for 2012-13 2Journal Article Suggests DermaClose® RC Used in Combination With VAC Therapy Can Dramatically Reduce the Need for Skin Grafting of Fasciotomy Wounds for Combat Related Trauma 2
(Date:7/30/2015)... ... July 30, 2015 , ... " ... which takes a look at small, medium, and large businesses making an impact ... conducted the business review and shared with viewers how DevExpress has provided software ...
(Date:7/30/2015)... ... July 30, 2015 , ... The Beryl Institute ... Program. In partnership with Patient Experience Institute, these offerings reinforce the commitment to ... front lines and throughout the experience movement, and provide information and research to ...
(Date:7/30/2015)... ... July 30, 2015 , ... Glidewell Laboratories, ... issue of Inclusive™ magazine, its multimedia publication focused on implant dentistry, is now ... new issue, Volume 6, Issue 2, as well as past issues of the ...
(Date:7/30/2015)... ... , ... Between 2012 and 2014 HIV infection rates rose from five to ... 17th. Those untreated heroin use disorders share their needles and spread the infection. Florida ... the community. Ultimately Florida’s HIV infection rates have bolstered to 23 percent due to ...
(Date:7/30/2015)... ... 30, 2015 , ... The New Jersey Innovation Institute (NJII), ... of Health, has received a $2.9 million grant from the Office of the ... Health and Human Services (HHS). NJII will help the Department of Health ensure ...
Breaking Medicine News(10 mins):Health News:Software to Develop High-Performance Data-Driven Apps was Featured on NewsWatch Television 2Health News:The Beryl Institute Opens Applications for 2015 Patient Experience Grant and Scholar Programs 2Health News:The Beryl Institute Opens Applications for 2015 Patient Experience Grant and Scholar Programs 3Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 2Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 3Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 4Health News:HIV Rates Rise in S. Florida, Harbor Village Comments on Health News Florida's Recent Article 2Health News:HIV Rates Rise in S. Florida, Harbor Village Comments on Health News Florida's Recent Article 3Health News:New Jersey Innovation Institute Awarded $2.9 Million Federal Grant to Advance Health Information Technology Services to Support Health Information Exchange 2
... ... the New Jersey non-profit Crossroads for Growth is determined to draw attention to the state’s ... ... 94 New Jersey families whose children struggle with autism spectrum disorders , finding financial ...
... ... ... , ... ...
... ... in Averill Park, New York will host two seminars teaching meditation and yoga as ... of Healing and Living: A Surgical Faith Lift ,” April 17, 2010. ... present “ Cancer Care: The Healing Power of the Mind ” April 14, 2010. ...
... ... ... , , , ... ...
... with heart disease will benefit from less invasive transcatheter ... updated practices in CMAJ ( Canadian Medical ... The most effective treatment for aortic stenosis, a ... consciousness due to lack of blood flow, congestive heart ...
... ... ... ... ...
Cached Medicine News:Health News:Crossroads for Growth Drawing Attention This World Autism Day to Help NJ Families Obtain Autism Treatment 2Health News:Crossroads for Growth Drawing Attention This World Autism Day to Help NJ Families Obtain Autism Treatment 3Health News:New Report Says African-Americans and Hispanics More Likely to Have Alzheimer's Disease And Dementia Than Whites 2Health News:New Report Says African-Americans and Hispanics More Likely to Have Alzheimer's Disease And Dementia Than Whites 3Health News:New Report Says African-Americans and Hispanics More Likely to Have Alzheimer's Disease And Dementia Than Whites 4Health News:New Report Says African-Americans and Hispanics More Likely to Have Alzheimer's Disease And Dementia Than Whites 5Health News:New Report Says African-Americans and Hispanics More Likely to Have Alzheimer's Disease And Dementia Than Whites 6Health News:New Report Says African-Americans and Hispanics More Likely to Have Alzheimer's Disease And Dementia Than Whites 7Health News:New Report Says African-Americans and Hispanics More Likely to Have Alzheimer's Disease And Dementia Than Whites 8Health News:New Report Says African-Americans and Hispanics More Likely to Have Alzheimer's Disease And Dementia Than Whites 9Health News:The American Meditation Institute Hosts Mind-Body Medicine,Seminars by Dr. Bernie Siegel, Leonard Perlmutter and Dr. Beth Netter 2Health News:The American Meditation Institute Hosts Mind-Body Medicine,Seminars by Dr. Bernie Siegel, Leonard Perlmutter and Dr. Beth Netter 3Health News:The American Meditation Institute Hosts Mind-Body Medicine,Seminars by Dr. Bernie Siegel, Leonard Perlmutter and Dr. Beth Netter 4Health News:MSPP Continues Commitment to the Mental Health of Veterans 2Health News:MSPP Continues Commitment to the Mental Health of Veterans 3Health News:MSPP Continues Commitment to the Mental Health of Veterans 4Health News:MSPP Continues Commitment to the Mental Health of Veterans 5Health News:MSPP Continues Commitment to the Mental Health of Veterans 6Health News:New heart valve replacement technologies offer hope for high-risk patients 2Health News:Diet and Healthy Weight Tips for National Nutrition Month from Patients Medical 2Health News:Diet and Healthy Weight Tips for National Nutrition Month from Patients Medical 3Health News:Diet and Healthy Weight Tips for National Nutrition Month from Patients Medical 4Health News:Diet and Healthy Weight Tips for National Nutrition Month from Patients Medical 5
The Minilyser offers a combination of three well proven instruments for fully automated processing of microplates. The Minilyser is the optimal fully automated ELISA and EIA equipment for laboratorie...
... Anti-Nuclear Antibodies (ANAs) has long been an ... rheumatic diseases. The antigens used in their ... of human or animal nuclei, this has ... Antigens (ENAs). The most commonly measured ENA ...
... Enzyme-linked immunosorbent assays for ... IgG antibodies to extractable nuclear ... (Ro), or SS-B (La)] in ... SS-B (La) antibodies aid in ...
... Diagnostic Automation, Inc. (DAI) ENA Profile Enzyme-Linked ... detection of antibodies in human serum to ... (La), Scl-70 and Jo-1 in a single ... are to be used as an aid ...
Medicine Products: